Injectable Drug Delivery Market: Global Industry Analysis and Forecast (2024-2030) by Devices, Formulations, Formulation Packaging, Therapeutic Application, Usage Pattern, Site of Administration, Patient Care Setting and Distribution Channel

Global Injectable Drug Delivery Market Overview

The field of drug delivery encompasses techniques and procedures to administer pharmaceutical compounds effectively in humans and animals. This research area focuses on developing novel materials and carrier systems to treat various ailments, with drug delivery systems that are steady, controlled, or targeted. Technologies like BioMEMs have revolutionized the Global Injectable Drug Delivery Market, introducing innovations such as transdermal drug delivery, implantable systems, and microfabricated carriers enhancing drug bioavailability and targeting capabilities.

 

Key Innovations and Examples in the Global Injectable Drug Delivery Market include Microneedle Arrays where tiny needles thinner than human hair penetrate the skin painlessly, delivering medications. NIBIB-funded scientists are developing dissolvable microneedle patches for vaccines, which are user-friendly and do not require refrigeration, making them suitable for low-resource areas. Injectable Drug Delivery Systems including intravenous (IV), subcutaneous (SC), and intramuscular (IM) routes, are popular due to their 100% bioavailability and fast onset of action. They are alternatives for drugs poorly absorbed orally.

 

With advancements in Medicare and the increasing prevalence of life-threatening diseases, healthcare professionals are shifting from oral medications to injectable systems. Pharmaceutical companies are leveraging this opportunity by developing efficient devices like injectables, prefilled syringes, auto-injectors, and pen-injectors for chronic conditions such as diabetes, hypertension, and arthritis. The U.S., with over 11.6% of its population diagnosed with diabetes, represents a significant market.

 

The Global Injectable Drug Delivery Market is driven by various Technological Advances and Trends Needle-free injectors Including prefilled syringes, auto-injectors, pen-injectors, and wearable devices, are rapidly growing segments. Pre-filled syringes are expected to held the highest market share in 2023, due to the increasing prevalence of diseases like diabetes, cancer, and autoimmune disorders. Biologics Drug Delivery where the popularity of biologics via injectables supports market growth, necessitating stringent regulatory guidelines for safety and quality. The market faces Challenges that include infections from contaminated needles, product recalls, and needle stick injuries. However, the rising demand for generic injectables and biosimilars offers significant growth opportunities, particularly in emerging markets like Brazil, India, and China.

 

The Global Injectable Drug Delivery Market has various applications where Injectable drugs are crucial in treating chronic infections such as HIV/AIDS and tuberculosis, often involving a combination of oral antibiotics and injectables. Injectable vaccines, such as those for influenza, stimulate the immune system to produce antibodies, preventing infections. Overall, The Global Injectable Drug Delivery Market is poised for growth due to the increasing prevalence of cancer and diabetes and the development of safety syringes, prefilled syringes, and auto-injectors.

 

Despite the presence of alternative drug delivery methods and safety concerns, the future of the injectable drug delivery market looks promising with the expected rise in demand for generics and biosimilars. In summary, the injectable drug delivery market is characterized by continuous innovation and growth driven by technological advancements, rising disease prevalence, and evolving healthcare practices.

 

To get more Insights: Request Free Sample Report

 

Global Injectable Drug Delivery Market Trend

Reusable and Disposable Injection Pens Recent years have witnessed a surge in reusable and disposable (pre-filled) injection pens from Global Injectable Drug Delivery Market leaders. These devices feature digital dose memory, new dosing mechanisms, and user-friendly designs, significantly boosting their adoption.

 

Needle-Free Delivery Systems and Auto-Injectors Needle-free delivery products have gained substantial traction in the healthcare market. Initially met with skepticism in the early 2010s, these products have evolved considerably with the involvement of leading medical companies. Auto-injectors, once considered futuristic, are now commonly used, further contributing to the Global Injectable Drug Delivery Market growth.

 

SAE’s 2024 Injectable Drug Delivery Conference This conference gathers top pharmaceutical experts to discuss the relationship between drug formulation and device packaging, offering case studies and technical updates that provide insights into optimizing injectable portfolios.

 

Global Injectable Drug Delivery Market Dynamics

Drivers

Injectable drug administration plays a critical role in treating various infectious disorders such as bacterial, viral, fungal, and parasitic infections. Many antibiotics, antiviral treatments, antifungal agents, and antiparasitic therapies are administered intravenously to achieve quick and effective drug concentrations in the bloodstream and target tissues. Injectable drugs are extensively used to manage chronic infectious diseases like tuberculosis (TB) and HIV/AIDS. For TB, treatment often combines oral antibiotics with injectable treatments such as rifampin, isoniazid, and streptomycin to effectively target TB bacteria and prevent drug resistance. Similarly, injectable antiretroviral medications are crucial in HIV/AIDS therapy to inhibit viral replication and slow disease progression in the Global Injectable Drug Delivery Market.

Factors driving the Global Injectable Drug Delivery Market are:

• Increasing Incidences of Chronic Diseases: The rising prevalence of chronic diseases such as cancer globally is a primary driver of the Global Injectable Drug Delivery Market. This is due to the effective and focused drug release with minimal side effects. In Nov 2023, the US Food and Drug Administration (FDA) approved the first and only obesity medication, Eli and Lilly’s Zepbound injection.

• Rising Geriatric Population: The growing elderly population drives the demand for the Global Injectable Drug Delivery Market, as older individuals often require a higher supply of medications and dosages for various age-related ailments.

• Growth in Biologics and Biosimilars Market: The expanding global market for biologics and biosimilars significantly contributes to the growth of the Global Injectable Drug Delivery Market.
• Shift from Vial-and-Syringe to Pre-filled and Reusable Syringes: Traditional vial-and-syringe formats are prone to dosing errors and infections. Pre-filled syringes and reusable glass syringes offer a safer and more effective mode of drug delivery, fueling the Global Injectable Drug Delivery Market growth.

 

Opportunities:

The growing demand for biosimilars and generic injectable pharmaceuticals presents significant opportunities for pharmaceutical companies to diversify their product portfolios in the Global Injectable Drug Delivery Market. By developing and manufacturing a wide range of injectable biosimilars and generic pharmaceuticals, companies address various therapeutic areas, such as oncology, autoimmune diseases, diabetes, and infectious diseases. This approach meets the increasing demand for affordable and accessible treatments. Biosimilars and generic injectable drugs are less expensive and more affordable than brand-name medications, making them more accessible to individuals, healthcare providers, and healthcare systems.

 

Injectable drug delivery systems play a critical role in administering these medications, ensuring safe, effective, and convenient delivery options for patients undergoing long-term or chronic therapies. The increasing number of research and development activities is expected to boost market opportunities during the forecast period. Advanced prodrug implants, chip-based drug delivery, and other technological advancements to drive market growth in injectable drug delivery. By capitalizing on these opportunities, pharmaceutical companies significantly contribute to the expansion and improvement of the Global Injectable Drug Delivery Market.

 

Challenges Global Injectable Drug Delivery Market

• Preference for Other Modes of Delivery: The injectable mode of drug delivery, while achieving rapid systemic absorption due to the increased surface area, faces significant challenges. Issues such as needle stick injuries, infections, needle phobia, anxiety, and discomfort limit the market for injectables. In contrast, the oral route remains the most preferred due to its ease of use, convenience, cost-effectiveness, safety, and acceptability. Injuries and infections caused by needles present ongoing challenges. These health risks contribute to a preference for alternative delivery methods and further delay Global Injectable Drug Delivery Market growth.
• Frequent Product Recalls: The market for injectable medicine delivery technology has faced multiple product recalls in recent years, either voluntarily or due to regulatory actions. Recalls are often prompted by contamination from inorganic materials like glass, silicone, and stainless steel, or improper vial filling. These incidents pose a significant challenge to the Global Injectable Drug Delivery Market growth during the forecast period of 2024-2030.
• Lack of Awareness and Preference for Alternative Methods: The growing use of alternative delivery methods and a general lack of awareness about the benefits of injectable delivery methods are additional restraints to market expansion.

 

Global Injectable Drug Delivery Market Segment Analysis

Based on Formulations: The formulations segment of the Global Injectable Drug Delivery Market is projected to experience the highest growth during the forecast period. Injectable formulations address a wide range of therapeutic needs, including oncology, diabetes, autoimmune diseases, cardiovascular diseases, and infectious diseases. Each therapeutic category often requires unique formulations tailored to the drug's properties and patient needs, contributing to the segment's diversity. Continuous advancements in drug delivery technology enable the development of novel formulations with improved features such as sustained release, targeted distribution, and increased stability. These innovations drive market expansion by enhancing the variety of injectable formulations available to healthcare providers and patients.

 

Based on Therapeutic Application: The infectious diseases segment held the largest share of the Global Injectable Drug Delivery Market in 2023. Vaccines play a crucial role in preventing infectious diseases and mitigating their public health impact. Injectable vaccines are commonly used in immunization programs against various infectious diseases, including influenza, measles, polio, hepatitis, and human papillomavirus (HPV). The high share of injectable vaccines in this segment is attributed to their development, production, and distribution. The global burden of infectious diseases, the challenges of antimicrobial resistance, hospital-acquired infections, the impact of globalization and travel, and the critical role of vaccines in disease prevention and control further emphasize this segment's significance.

 

Based on the Site of Administration: The skin/intradermal site of administration accounted for the highest share of the Global Injectable Drug Delivery Market during the forecast period. Subcutaneous injections, compared to intravenous or intramuscular injections, are easier to administer and do not require specialized medical knowledge or equipment. Healthcare personnel effortlessly provide subcutaneous injections in various clinical settings, such as clinics, hospitals, and home healthcare. The subcutaneous tissue's robust blood supply and large surface area facilitate quicker and more consistent drug absorption into the bloodstream, making it suitable for drugs requiring steady-state plasma concentrations and predictable pharmacokinetics.

 

Based on the End User: The end-user segment includes hospitals, clinics, home care settings, and others. Hospitals are expected to dominate the Global Injectable Drug Delivery Market share during the forecast period due to the increased number of patients with chronic or acute wounds requiring extended hospital stays. The clinics segment is anticipated to grow at a significant compound annual growth rate (CAGR) due to the rising number of stand-alone clinics in developed and emerging countries. Additionally, the home care settings segment is projected to register significant growth by the end of the forecast period, driven by the rising preference among patients for home care over hospital care.

 

Injectable Drug Delivery Market Regional Analysis/Insights

North America leads the Global Injectable Drug Delivery Market due to the high adoption of advanced injectable drug delivery systems and a substantial patient base. The region's market is driven by the prevalence of diabetes and cancer, which fuels the demand for innovative technologies such as smart wearables and auto-injectors. The American Diabetes Association reported approximately 30.3 million Americans with diabetes in 2018, contributing to the market's growth.

 

In Europe, the U.K. is seeing growth in the Global Injectable Drug Delivery Market, with a projected CAGR of xx% through 2034. This growth is largely due to the rising obesity rates, which have prompted the development of weight-loss injectables. The Health Survey for England 2021 indicates that 25.9% of adults are obese, leading to innovations like Eli Lilly's injectable diabetes medication approved for weight loss.

 

Global Injectable Drug Delivery Market Scope

Global Injectable Drug Delivery Market
Market Size in 2023	USD 752.95 Bn.
Market Size in 2030	USD 1561.27 Bn.
CAGR (2024(2030)	10.98%
Historic Data	2018-2022
Base Year	2023
Forecast Period	2024-2030
Global Injectable Drug Delivery Market Segments	By Devices Conventional Injection Devices Self-injection devices Needle-free Injectors Autoinjectors Pen Injectors Wearable Injectors Other Devices
	By Formulations Conventional Drug Delivery Formulations Microparticles Long-Acting Injection Formulations
	By Formulation Packaging Ampules Vials Cartridges Bottles
	By Therapeutic Application Autoimmune diseases HORMONAL DISORDERS Orphan diseases Cancer Infectious diseases Other therapeutic applications
	By Usage Pattern Curative care Immunization Others
	By Site of Administration Skin(Intradermal and subcutaneous) Circulatory/Musculoskeletal system (Intravenous, Intracardiac, Intramuscular and Intraperitoneal) Organs (Intravitreal and Intra-articular) Central Nervous system ( Intracerebral and intrathecal)
	By Distribution Channel Hospitals Retail Pharmacy stores
	By Patient Care Setting Hospitals and Clinics Home care settings Other facilities of Use
Regional Scope	North America (United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Russia, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa ( South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America

 

Global Injectable Drug Delivery Market Key players

North America

1. Becton, Dickinson, and Company (U.S.)
2. Pfizer Inc. (U.S.)
3. Eli Lilly and Company (U.S.)
4. Baxter International, Inc. (U.S.)
5. Abbott (U.S.)
6. Johnson & Johnson Private Limited (U.S.)
7. Mylan N.V. (U.S.)
8. Merck & Co., Inc. (US)
9. Amgen Inc. (US)
10. Biogen Inc. (US)
11. Bristol Myers Squibb Company (US)

Europe

1. Sandoz (Germany)
2. Schott AG (Germany)
3. Gerresheimer AG (Germany)
4. B. Braun Melsungens (Germany)
5. Novartis AG (Switzerland)
6. AstraZeneca (U.K.)
7. Sanofi (France)
8. Novo Nordisk A/S (Denmark)
9. GlaxoSmithKline plc (UK)
10. Roche Holding AG (Switzerland)

Asia Pacific

1. Terumo Medical Corporation (Japan)
2. CSL Limited (Australia)

Middle East and Africa (MEA)

1. Teva Pharmaceuticals Industries Ltd. (Israel)
2. E3D Elcam Drug Delivery Devices (Israel)